LABT Lakewood-Amedex Biotherapeutics Inc.
Listings ·
Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.
Holders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20.
Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.
The company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning.
Our latest story on this, dated Sep 29, 2026: "Lakewood-Amedex holders approve share increase and reverse split authority". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The story links the filing or release it is based on. Read the story.
Lakewood-Amedex Biotherapeutics Inc. trades under the ticker LABT on NASDAQ.
Lakewood-Amedex Biotherapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lakewood-Amedex Biotherapeutics Inc. is 2079272. Its filings are on SEC EDGAR.
2,369,688 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Lakewood-Amedex Biotherapeutics Inc. under United States.
Our directory classifies Lakewood-Amedex Biotherapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lakewood-Amedex Biotherapeutics Inc. is US51255A2015.
aibio.space lists Lakewood-Amedex Biotherapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Our latest story on Lakewood-Amedex Biotherapeutics, dated Sep 29, 2026: "Lakewood-Amedex holders approve share increase and reverse split authority". Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty. Source.
Our latest financing story, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning. Source.
From our story: RBW Capital Partners LLC is the company's financial advisor for the listing, under a February 10, 2025 agreement covering financial advisory, financial placement agency and investment banking services. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio